Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-24-016119
Filing Date
2024-12-10
Accepted
2024-12-10 16:05:15
Documents
5
Period of Report
2024-12-10

Document Format Files

Seq Description Document Type Size
1 6-K tmb-20241210x6k.htm 6-K 19110
2 EX-99.1 tmb-20241210xex99d1.htm EX-99.1 978388
3 EX-99.2 tmb-20241210xex99d2.htm EX-99.2 172560
4 EX-99.3 tmb-20241210xex99d3.htm EX-99.3 291074
5 GRAPHIC tmb-20241210xex99d3001.jpg GRAPHIC 7883
  Complete submission text file 0001558370-24-016119.txt   1473256
Mailing Address YALELAAN 62 UTRECHT P7 3584 CM
Business Address YALELAAN 62 UTRECHT P7 3584 CM 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40241 | Film No.: 241538475
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)